Press Releases Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 16:31:35 16/02/2026 GMT			5-day change	1st Jan Change
126.46 ^CHF	+1.05%		+5.21%	+15.38%

02-13	Sector Update: Health Care Stocks Advance Late Afternoon	MT
02-13	Sector Update: Health Care Stocks Higher Friday Afternoon	MT

Press Releases

09:03am	Novartis : Q4 2025 impact and sustainability update	PU
02-13	Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy	GL
02-09	Novartis : ESG Data Summary 2025	PU
02-09	Novartis : Update	PU
02-09	Novartis : SASB index	PU
02-06	Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery	GL
02-06	Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery	GL
02-04	Novartis: Q4 Earnings Snapshot	AQ
02-04	Novartis : Report	PU
02-04	Novartis : Earnings Document (q4 2025 investor presentation)	PU
02-04	Novartis : Earnings Document (q4 2025 interim financial report en)	PU
02-04	Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025	GL
01-30	NFL Greats and Novartis Tackle Prostate Cancer Myths at Super Bowl LX, Relax, It's a Blood Test	AQ
01-16	Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease	GL
01-15	Letter to global governments: A call for bold life sciences investment	PU
01-09	Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment	GL
01-09	Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment	GL
12-19	Novartis and US government reach agreement on lowering drug prices in the US	GL
12-12	Novartis breaks ground on flagship manufacturing hub in North Carolina	GL
12-12	Market Outlook: Injectable Drug Delivery Industry to Top US$1,034.78 Billion by 2030	AQ
12-09	Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses	GL
12-09	1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years	GL
11-25	Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS	GL
11-24	Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)	GL
11-20	Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Novartis: Markets happy with Novartis's delivery

February 04, 2026 at 04:40 pm

Novartis CEO Says They Will Have to 'Tackle Rhetoric' in US Healthcare

January 21, 2025 at 10:56 am